Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Following a major outbreak involving the use of tear drops in 13 US states, experts are offering advice on how to protect dry eyes.
Read Full NewsThe history of lobotomy shows the risks for limited evidence and oversight, while modern approaches emphasize targeted treatment, informed consent, and rigorous evaluation.
US radiologists vary substantially in their reading of low-dose CT lung cancer screens, highlighting a need for measures to help standardize interpretation.
Researchers compare first-line chemotherapy regimens in older patients with classical Hodgkin lymphoma to assess whether AVD is associated with better outcomes in routine care.
Researchers analyze individual patient data from five randomized phase 3 trials comparing PORT alone vs PORT plus hormone therapy in patients with recurrent prostate cancer.
A new real-world analysis helps clarify the most informative prognostic PSA benchmark in men with metastatic castration-sensitive prostate cancer.
Tissue-free ctDNA may be comparable to tumor-informed assays in detecting molecular residual disease.
1.
Metastatic Cancer 'Thrivers'; Celebrity Cancer Diagnoses; 'Would He Have Lived?'
2.
Can certain food cravings predict a cancer diagnosis up to three months before other symptoms appear?
3.
When in Breast Cancer Treatment Are CDK4/6 Inhibitors Best?
4.
How the metastasis of cancer is driven by cellular plasticity.
5.
Mortality up for children with leukemia from lowest SES neighborhoods
1.
Ferroptosis-Modulating Therapies for Treatment-Resistant Malignancies
2.
Thyroid Cancer and Insulin Resistance: Unraveling the Complex Interplay for Better Patient Outcomes
3.
A New Hope: Exploring the Benefits of Exenteration for Cancer Patients
4.
Practical Directions in Oncology in Daily Practice
5.
Teaching Hematology Through Morphology-Based Learning
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
2.
Understanding Platelet Disorders
3.
Navigating the Complexities of Ph Negative ALL - Part VII
4.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
5.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge